Mike Lam

Mike Lam represents high-growth companies and investment banks on capital markets and corporate transactions, including initial public offerings, other equity offerings, high-yield and investment-grade offerings, and acquisition financing. Mike also has experience counseling clients on general corporate and securities matters, including mergers and acquisitions, private equity and venture capital investments, SEC reporting obligations, and corporate governance.

Mike’s select representative matters include advising:

Capital markets

• Grindr in its $2.1 billion de-SPAC business combination with Tiga Acquisition Corp. and its ongoing corporate and public company matters
• Heliogen in its $2.0 billion de-SPAC business combination with Athena Technology Acquisition Corp.
• Annexon Biosciences in its $125.0 million registered direct offering
• Aspira Women’s Health in its $5.5 million registered direct offering and concurrent private placement and ongoing corporate and public company matters
• Resideo in its $255.0 million follow-on offering*
• The underwriters in Sagimet Biosciences’:
  • $85.0 million IPO
  • $112.5 million follow-on offering
• The underwriters in Apogee Therapeutics’ $345.1 million IPO
• The underwriters in DICE Therapeutics’ $234.6 million IPO
• The underwriters in Ventyx Biosciences’ $174.3 million IPO
• The underwriters in Qualtrics’ $1.15 billion follow-on offering
• The underwriters in 89bio, Inc.’s $172.5 million follow-on offering
• The underwriters and initial purchasers in Ascendis Pharma’s:
  • $460.0 million follow-on offering
  • $575.0 million offering of 2.25% convertible senior notes due 2028
• The initial purchasers in Global Blood Therapeutics’ $345.0 million offering of 1.875% convertible senior notes due 2028
• The underwriters in IGM Biosciences’:
  •  $230.0 million follow-on offering
  • $97.5 million follow-on offering and $22.5 million concurrent private placement
• The underwriters in Arcutis’ $172.5 million follow-on offering
• The underwriters in LumiraDX’s $75.3 million follow-on offering and $25.0 concurrent private placement
• The underwriters in Vistagen Therapeutics’ $100.0 million follow-on offering
• The underwriters in Erasca’s $100.0 million follow-on offering
• The underwriters in Acutus Medical’s $77.0 million follow-on offering
• The placement agents in Annexon Biosciences’ $130.0 million private placement

Mergers & acquisitions, private equity, and emerging companies & venture capital

• Atlas Holdings in its acquisition of LSC Communications, pursuant to Section 363 of the U.S. Bankruptcy Code*
• Cisco in its acquisition of ThousandEyes*
• Brinker Capital in its sale to Genstar Capital and subsequent merger with Orion Advisor Solutions*
• Exela Technologies in its:
• $160.0 million accounts receivable securitization facility*
• carve out sale of SourceHOV Tax to Gainline Capital Partners*
• corporate and public company matters*
• Andreessen Horowitz in its investment in the $20.0 million Series A financing of Stacker
• Altos Labs in its ongoing private company matters
• Full In Partners in its investment in the Series B financing of AutoRABIT*
• Insight Partners in its investments in:
• The Real Brokerage*
• Hinge Health*

*Representation handled prior to joining Cooley

Before joining Cooley, Mike was a corporate associate in the New York office of Willkie Farr & Gallagher.

During law school, Mike represented social enterprises, nonprofit organizations and select small businesses as a student attorney in the Social Enterprise and Nonprofit Law Clinic, served as a staff editor and community outreach director of the Georgetown Journal on Poverty Law and Policy, and worked as a research assistant for Professor Robert B. Thompson. Mike also externed in the Division of Enforcement’s Whistleblower Office of the U.S. Commodity Futures Trading Commission.

Prior to law school, Mike worked in the channel operations, compensation and marketing departments of a Canadian telecommunications provider, where he helped develop and implement strategic marketing initiatives, incentive programs, and channel compensation systems.